Feature | November 14, 2007 | Cristen C. Bolan

Getting to the Bottom of Data Mining

Decision support assists in designing individualized treatments with better outcomes, less complications, that are more cost-effective.

The more knowledge a physician has about a disease, the better equipped he or she is to care for the patient. That is the idea behind leveraging clinical information for decision support. The future of knowledge-driven clinical decision support is about being able to analyze all available information from patient records and make inferences based on this information.
One of the most cutting-edge clinical decision-support projects today is underway between Siemens Medical Solutions and MAASTRO (Maastricht Radiation Oncology), a leading radiation oncology treatment center in the Netherlands. They are jointly developing an application called REMIND Clinical Decision Support (CDS).
The REMIND platform (Reliable Extraction and Meaningful Inference from Nonstructured Data) includes data extraction such as natural language processing or proteomic analysis, data combination and probabilistic inference. REMIND is designed to search through all patient records, analyzing demographics, clinical factors, imaging information, treatment plans, delivered treatment, genomics and proteomics.
To get to the bottom of this new data mining technology, Imaging Technology News interviewed Professor Philippe Lambin, the clinical head of radiation oncology at MAASTRO, the Radiology Oncology Treatment Center in The Netherlands, about REMIND technology.
How is decision support currently being used in the clinical setting?
We want to develop it for lung cancer, and, for each patient, we want to be able to compare different types of treatment, and for each treatment have a prediction of complication and outcome. For late lung cancer it would be specifically survival at two years and late lung complication and early esophageal complications. These predictions should be validated using objective numbers to make a decision and take into account the wishes of the patients.
Are there any statistics to demonstrate how decision support improves patient outcome?
While there is more experience in radiology, in radiotherapy (RT) there aren’t any statistics to demonstrate how decision support improves patient outcome. There is modeling of theoretical considerations.
We know in RT that the higher dose you can give, the better the outcome. The dose is determined not so much by the outcome you want to reach, but more by the complication. If you have better predictions of the complications, you can anticipate through various treatments what the maximum tolerated dose will be and therefore have a better outcome. This is modeling of theoretical considerations, but to my knowledge there is no real clinical data in radiation therapy.
What are some of the challenges in developing a decision-support solution?
The biggest challenge in my eyes is to get good data, complete clinical data, to build the predictive algorithm. Because the algorithms are quite powerful to predict you also need to gather independent sets of data. We call them training data sets. You make a first algorithm, and then you have to validate this algorithm on independent validation data sets. It’s even better if data sets come from different centers.
Linked to that you need to build a large database to gather all of this data, and you need a database for imaging, validating data and also comparing quality of the treatment. That is the difference between radiotherapy and radiology – the quality of the treatment. You could have, in theory. a tumor with very good prognosis, but if the treatment is bad the patient will die. So you have to incorporate quantitative data on quality of treatment. And that is not so obvious.
What are some of the key features of the solution Siemens is developing in collaboration with MAASTRO?
A tool will tell the doctor what would be the extra diagnostic procedure that would be most efficient to improve the prediction. You can also give advice about an extra diagnostic procedure that would be most cost-efficient. The system can tell you that this PET scan will be the most efficient diagnostic tool to further improve your prediction. But a blood sample would be the most cost-efficient. So it would less efficient not to use the PET scan, but it’s the most cost-efficient method because a blood sample is much cheaper than a PET scan. This will be part of the REMIND platform.
To date, what has your research involved?
There are applications for research and development of new treatments and drugs. With molecular targeting drugs, we know that these new, very expensive drugs are only efficient on a subgroup of patients. The decision support will help the researchers focus on specific subgroups of patients who are more likely to benefit from the treatment. That will make it possible to have shorter, less expensive clinical trials.
There already is a prototype of REMIND, and version two was shown at ASTRO 2007 (American Society for Therapeutic Radiology and Oncology), but it is not yet commercialized. In patient care it is a tool to help the doctor, not a determinant.
How will decision support develop in the future?
We are extending it to several centers, and will let them develop the tool – and add more patients, more data and greater validation data set for training.
For patient care, the ultimate step is to validate the decision tool using evidence-based medicine approaches. The way we see it is when we are quite confident with the tools, we will compare, for example, state-of-the-art treatments for lung cancer versus individualized treatments based on the decision support, where in theory all of the patients could have received different treatments. The hypothesis is that with individualized treatments based on decision support, the outcome should be better and with less complications, and it will also be more cost-effective.

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a

While subject No. 1 (left) was judged as positive for both the neuronal injury and the amyloid load biomarker, both Alzheimer's disease biomarkers were negative in subject No. 2 (right). Image courtesy of Henryk Barthel et al., University Hospital Leipzig, Leipzig, Germany

News | PET Imaging | June 14, 2017
More people die of Alzheimer's disease than prostate and breast cancer combined. Identifying the disease before major...
News | Clinical Study | June 09, 2017
The milestone Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study is working with government and academic...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced t
low-dose lung CT scan

An example of a low-dose CT scan of the lungs, showing lung cancer. Image courtesy of Toshiba.

Feature | Lung Cancer | May 05, 2017 | Alison Grimes
The term mesothelioma was coined in 1909, just a few years after the introduction of medical X-ray imaging.
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
April 28, 2017 — Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the devel
Overlay Init